Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesdav Jutv 9

Poster Exiiin Tueda -- l 7 1--Q

TuPeA4424 High throughput screening assay for studying HIV
genetic diversity in Asia
V Watanaveerade1, j K Carr2, M Hoelscher3,
M Benenson', A E Brown', D Birx2, F E McCutchan2
( Thailand; 2United States; 3Germany)
TuPeA4426 Viral load of human herpesvirus-8 in peripheral
blood of human immunodeficiency virus-infected
patients with Kaposi's Sarcoma and Primary
Effusion Lymphoma
R Tedeschi', E Bidoli, M Enbom2, A Linde 2,
J Dillner2, C Simonelli', P De Paoli'
(Italy; 2Sweden)
TuPeA4427 KSHV/HHV8 cell association during AKS and EKS
evolution
E E Kaaya, P Pyakurel2, C G Massambu2,
T Heiden2, E Castanos-Velez2, M Enbom2,
P Biberfeld 2 (Tanzania; 2Sweden)
TuPeA4428 NK cell activity controls HHV-8 latent infection
and is restored upon HAART in AIDS patients with
regressing Kaposi's sarcoma
M C Sirianni, L Vincenzi, S Topino, F Libi,
D Scaramuzzi, M Campagna, P Monini, B Ensoli
(Italy)
TuPeA4429 Identification of cytotoxic T lymphocyte epitopes
of human herpes virus 8
F Micheletti, P Monini, C Fortini, P Rimessi,
M Andreoni, M Giuliani, B Ensoli, R Gavioli (Italy)
TuPeB443o Overview of the comparative effectiveness of
Tuesday triple combination therapy regimens of
emtricitabine (FTC) and lamivudine (3TC) in
antiretroviral-naive HIV-1 infected adults
C Benson I B Quinn, C Wakeford, C Moxham,
F Rousseau (United States)
TuPeB4431 Phase 1 multiple oral dose safety and
pharmacokinetic study of S-136o, an H IV
integrase inhibitor with healthy volunteers
T Fujiwara (United States)
TuPeB4432 Two randomized, controlled, equivalence trials of
emtricitabine (FTC) to lamivudine (3TC)
/ Sanne', C van der Horst2, A Shaw2, J Hinkle2,
j B Quinn2, C Moxham2, F Rousseau2
(ISouth Africa; 2United States)
TuPeB4433 Genotypic analysis of HIV-1 infected ART-naive
patients receiving emtricitabine (FTC) or lamivudine
(3TC) in a double blind equivalence trial
/ Sanne', J B Quinn2, j Harris2, A Shaw2, J Hinkle2,
K Borroto-Esoda2, C Moxham2, F Rousseau2
OSouth Africa; 2United States)
TuPeB4434 A passive immunotherapy, PEHRG214, in patients
infected with HIV-1: a phase I study
B jDezube', J A Proper', ] L Zhang', V J Choy2,
W Weeden', J Morrissey', J Carpenter', E Burns',
SD Dixon2, C O'Loughlin2, P1 Pickering2,
CS Crumpacker', F B Gelder
(United States; 2New Zealand)
TuPeB4435 Pre-clinical development of the antiretroviral drug
candidate PA-344B
C T Wild, N R Kilgore, M S Reddick, YD Asfaw,
K D Salzwedel, IA Turpin, L Xie, K H Lee,
P C Smith, G P Allaway, DE Martin (United States)
TuPeB4436 S-136o, a new HIV integrase inhibitor, repeatdose pharmacokinetics (PK) and safety in healthy
volunteers following oral administration
- Fujiwara, - Leese, - Lippert, - Russell
(United States)
TuPeB4437 Tipranavir/ritonavir: derivation of doses that
achieve effective plasma concentrations above

the IC5o for multiple PI-resistant HIV-1 viruses
S McCallister V Kohlbrenner, D Mayers
(United States)

TuPeB4438 One-week therapy with TMC125, a next
generation NNRTI, demonstrates high potency in
treatment-experienced HIV-1 infected individuals
with phenotypic NNRTI-resistance
B G Gazzard, A Pozniak, K Arasteh2,
S Staszewski2, W Rozenbaum3, P Yeni3,
G van 't Klooster4, K De Dierv4, M Peeters4,
M P de Bdthune4, N Graham5, R Pauwels4
(United Kingdom; 2Germany; 3France; 4Belgium;
5United States)
TuPeB4439 Three Year Immunologic Responses In
Atiretroviral-Naive H IV+ Patients Treated with
Lopinavir/ritonavir (Kaletra) Based Therapy
A Landa S Brun, M King, T Marsh, R Murphy,
C Hicks, J Eron, R Gulick, M Glesby, R Stryker,
M Thompson, C White, C Benson, M Albrecht,
H Kessler, E Sun (United States)
TuPeB444o The feasibility of HAART in a Northern Thai
cohort: 2000-2001
T Leusaree', K Srithanaviboonchai,
S Chanmangkang', L Ying-Rul, C Natpratan2
(1Thailand; 2Cambodia)
TuPeB4441 The SENC trial: a randomized, open-label study
comparing efavirenz versus nevirapine. Results at
48 weeks
M Nunez V Soriano, L Martin-Carbonero,
R Rodriguez-Rosado, B Diaz, J Gonzalez-Lahoz
(Spain)
TuPeB4442 Durability of nelfinavir based HAART
MA Horberq, DB Klein, TT Luu, K Sinn
(United States)
TuPeB4443 Durability and tolerability of nevirapinecontaining regimens in a cohort of antiretroviralnalve HIV-positive patients
N E Mackie C Sabin, R Weston, J N Weber
(United Kingdom)
TuPeB4444 High effectiveness of efavirenz-based HAART in HIVI infected patients with less than loo CD4 cells/mL
and opportunistic diseases. The EfaVI P-1 study
J R Arribas F Pulido, J M Mird, MA Costa,
j JGonzdlez, R Rubio, I M Pefia, M Torralba,
M Lonca, A Lorenzo, C Cepeda, J M Gatell (Spain)
TuPeB4445 Once-daily vs. twice-daily Kaletra
(lopinavir/ritonavir) in antiretroviral-naive HIV+
patients: 72 week follow-up
J Feinberg, Eron, B Bernstein, M King,
L Manning, R Bertz, G Beall, F Carpio-Cedraro,
H Horowitz, D Wheeler, H Kessler, D Mildvan,
P Ruane, B Yangco, E Sun (United States)
TuPe4446 Nelfinavir versus indinavir/ritonavir in treatment
naive patients: comparison of efficacy and safety
at one year
S De Wit1, R Boulmd2, D Konopnicki,
B Sommereijns', J P Protto, 0 Van der Meeren,
N Clumeck (Belgium, 2Luxembourg)
TuPeB4447 Efficacy of lopinavir/r (KaletraTM) in HIV- infected
patients with severe immune deficiency and/or
high viral load
G Fdtkenheuer, A Rieke, A Wbhrmann, S Mauss,
H Knechten, H Carls, K lsernhagen,
W Kdthemann, W Stdcker, A Schulz, M Oette,
W Wiesel, M Graab, I Rockstroh (Germany)
TuPeB4448 The effect of socio-economic factors on treatment
outcomes of H IV patients receiving AntiRetroviral therapy in Sagamu, Nigeria
O Falola, 0 Ogundahunsi, H 0Ogun,
M D Oduwole (Nigeria)

TuPeB4449 Automation of specimen preparation for HIV-1
viral load determination
V P Michel-Trei, A D Light2, KR Tau2
(Switzerland; 2United States)

94 Final Program